Key facts
- Hervolution Therapeutics’s last known valuation is $28.1M (Dec 2024).
- It has raised $15.7M; the latest was Later Stage VC ($7.7M) in Dec 2024.
- Notable investors include European Innovation Council, Novo Holdings, BioInnovation Institute, SeedFolio, Danish Business Innovation Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Hervolution Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Hervolution Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hervolution Therapeutics
Operator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome. The company offers broad and curative cancer therapy in combination with immune checkpoint inhibitors, enabling medical researchers to easily find treatment for cancer using adaptive immune therapy.
- Sector
- Healthcare
- HQ
- Frederiksberg, Denmark
- Founded
- 2011
- Employees
- 20
- Website
- hervolutiontx.com/
- Ownership
- Privately Held (backing)
Hervolution Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hervolution Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hervolution Therapeutics in its N-PORT filings yet. We sweep new filings monthly.